Skip to content

Novelion Therapeutics Inc.

CIK 0000827809

← back to feed
Revenue (TTM)
$130.43M
−5.8% YoY Q1 May 2019
Net Income (TTM)
−$120.75M
+21.7% YoY Q1 May 2019
EPS Diluted (TTM)
—
Q1 May 2019
Gross Margin
56.3%
Q1 May 2019
Operating Margin
-51.4%
Q1 May 2019
Net Margin
-92.6%
Q1 May 2019
Free Cash Flow (TTM)
−$48.81M
Q1 May 2019
Cash
$45.15M
Q1 May 2019
Total Debt
$89.72M
Q1 May 2019
Shares Outstanding
19.04M sh
Q1 May 2019

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings